EUVIMEDEUVIMED entdecken
Crossref

Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor co‐administration in patients with type 2 diabetes mellitus

Miyoung Ock, Sera Lee, Hyunah Kim iD

Journal of Clinical Pharmacy and Therapeutics · 2022-07 · 47 (7) · 1028-1035

DOI: 10.1111/jcpt.13640 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Pharmacy and Therapeutics, online erschienen am 07.03.2022. Verfasst von Miyoung Ock und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Sookmyung Women's University, Seoul, South Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Fractures, Bone, Osteoporosis, Thiazolidinediones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Research Foundation of Korea (NRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Fractures, BoneOsteoporosisThiazolidinedionesAdultFemaleHumansHypoglycemic AgentsProton Pump InhibitorsRetrospective StudiesRisk Factors

Stichwörter der Autor:innen

drug-drug interactionfractureosteoporosisproton pump inhibitorthiazolidinedione

Substanzen

Hypoglycemic AgentsProton Pump InhibitorsThiazolidinediones

Autor:innen und Institutionen

  • College of Pharmacy, Sookmyung Women's University, Seoul, South Korea.
  • Drug Information Research Institute, Sookmyung Women's University, Seoul, South Korea.

ORCID-Profile: Hyunah Kim

Förderung

  • National Research Foundation of Korea (NRF)

Zitieren

APA

Ock, M., Lee, S., & Kim, H. (2022). Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor co‐administration in patients with type 2 diabetes mellitus. Journal of Clinical Pharmacy and Therapeutics, 47(7), 1028-1035. https://doi.org/10.1111/jcpt.13640

Vancouver

Ock M, Lee S, Kim H. Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor co‐administration in patients with type 2 diabetes mellitus. Journal of Clinical Pharmacy and Therapeutics. 2022;47(7):1028-1035. doi:10.1111/jcpt.13640

BibTeX
@article{Ock2022,
  author = {Ock, Miyoung and Lee, Sera and Kim, Hyunah},
  title = {Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor co‐administration in patients with type 2 diabetes mellitus},
  journal = {Journal of Clinical Pharmacy and Therapeutics},
  year = {2022},
  volume = {47},
  number = {7},
  pages = {1028--1035},
  doi = {10.1111/jcpt.13640}
}
Kostenlos starten →